文献速递眼整形与眼眶神经眼科

丁酸盐通过调节眼眶成纤维细胞表型与肠道微生物群改善格雷夫斯眼病

Butyrate Ameliorates Graves' Orbitopathy Through Regulating Orbital Fibroblast Phenotypes and Gut Microbiota.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

本研究利用GO动物模型及来自健康人和GO患者的眼眶成纤维细胞,观察丁酸盐对眼眶成纤维细胞活力、活化、脂肪生成及肠道微生物群的影响。结果显示丁酸盐选择性降低GO来源成纤维细胞活力、抑制脂肪生成和TGF-β1诱导的纤维化,改善GO小鼠眼眶组织学异常并调节肠道菌群,提示其通过肠-甲状腺轴治疗GO的潜力。

要点

  • 丁酸盐显著降低GO来源眼眶成纤维细胞活力,不损伤正常成纤维细胞。
  • 丁酸盐抑制GO和正常眼眶成纤维细胞的脂肪生成及TGF-β1诱导的纤维化。
  • 丁酸盐改善GO小鼠眼眶组织学异常、正常化血清甲状腺激素和抗体水平并改变肠道菌群。

核心结论

  • 丁酸盐可改善GO的多个症状,降低GO眼眶成纤维细胞活力、脂肪生成和TGF-β1诱导的纤维化,且不损伤正常成纤维细胞。
  • 丁酸盐在GO小鼠模型中正常化甲状腺功能、改善组织病理学改变并改变肠道微生物群,证明其通过肠-甲状腺轴治疗GO的潜力。

研究设计与样本

  • 本研究利用GO动物模型,并用来自健康人和GO患者眼眶组织的成纤维细胞进行离体实验,评估丁酸盐对细胞活力、活化和脂肪生成的影响。
  • 研究还分析了丁酸盐治疗与未治疗GO小鼠的肠道微生物群多样性。

主要发现

  • 在人类眼眶成纤维细胞中,丁酸盐处理显著降低GO来源成纤维细胞的活力,而不损伤正常成纤维细胞。
  • 丁酸盐阻止GO和正常成纤维细胞中由转化生长因子β1(TGF-β1)诱导的活化和纤维化过程。
  • 丁酸盐减少GO和正常眼眶成纤维细胞的脂滴形成并下调脂肪生成标志物,抑制脂肪生成。
  • 在GO小鼠模型中,丁酸盐治疗改善眼眶组织学异常,并使血清甲状腺激素和抗体水平正常化。
  • 丁酸盐治疗的GO小鼠肠道微生物组发生显著变化,某些细菌(双歧杆菌属、GCA-900066575和副拟杆菌属)减少,另一些(拟杆菌属和Rikenellaceae_RC9)增加。

临床怎么用

  • 原文结论指出丁酸盐通过肠-甲状腺轴具有治疗GO的潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Graves' orbitopathy (GO), the common extrathyroidal complication of Graves' disease (GD), is characterized by orbital fibroblast stimulation, adipogenesis, and hyaluronan production. Recently, gut microbiota and its metabolites have garnered attention for their possible involvement in GO. METHODS: This study utilized an animal model of GO and examined the effects of butyrate treatment on orbital fibroblast cells and gut microbiota. Ex vivo experiments were performed using orbital fibroblasts derived from healthy patients' and patients' with GO orbital tissue to evaluate vitality, activation, and adipogenesis in response to butyrate treatment. Gut microbiota diversity was also analyzed in butyrate-treated and untreated GO mice. RESULTS: In human orbital fibroblasts, butyrate treatment dramatically decreased the vitality of GO-derived fibroblasts without harming normal fibroblasts. Butyrate prevented activation and fibrotic processes induced by transforming growth factor beta 1 (TGF-β1) in GO and normal fibroblasts. Additionally, butyrate reduced lipid droplet formation and downregulated lipogenic markers in GO and normal orbital fibroblasts, inhibiting adipogenesis. In the GO mouse model, butyrate therapy improved orbital histological abnormalities and normalized serum thyroid hormone and antibody levels. The intestinal microbiome of butyrate-treated GO mice also changed significantly, with a reduction in certain bacteria (Bifidobacterium, GCA-900066575, and Parabacteroides) and an increase in others (Bacteroides and Rikenellaceae_RC9). CONCLUSIONS: Butyrate ameliorates several of the symptoms of GO, lowering GO orbital fibroblast viability, adipogenesis, and TGF-β1-induced fibrosis without damaging normal fibroblasts. Butyrate normalizes thyroid function in a GO mouse model, improves histopathological alterations, and transforms gut microbiota populations, proving its potential in treating GO through the gut-thyroid axis.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Ouyang P, Qi J, Tong B, et al. Butyrate Ameliorates Graves' Orbitopathy Through Regulating Orbital Fibroblast Phenotypes and Gut Microbiota. Invest Ophthalmol Vis Sci. 2025. PMID: 40035727. doi:10.1167/iovs.66.3.5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。